Scilex HoldingSCLX
About: Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Employees: 115
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
138% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 8
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
22% more call options, than puts
Call options by funds: $39K | Put options by funds: $32K
9% more funds holding
Funds holding: 91 [Q3] → 99 (+8) [Q4]
0.53% less ownership
Funds ownership: 21.05% [Q3] → 20.52% (-0.53%) [Q4]
33% less capital invested
Capital invested by funds: $31.1M [Q3] → $20.9M (-$10.2M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for SCLX.
Financial journalist opinion
Based on 5 articles about SCLX published over the past 30 days









